Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) posted results of the Phase 1 trial of Amilo-5MER in healthy volunteers.

• Amilo-5MER is a synthetic peptide consisting of 5 amino acids that significantly reduces symptoms and histopathological hallmarks of Inflammatory bowel disease (IBD) in animal models (TNBS, DSS). 
• TNBS and DSS are well-established and widely recognized models of acute colitis. 
• Related: Galmed’s NASH Candidate Shows Clinically Significant Effect On Fibrosis Improvement.
• Amilo-5MER also showed anti-inflammatory effects in animal models of multiple sclerosis and rheumatoid arthritis. 
• Amilo-5MER binds with high affinity to pro-inflammatory amyloid proteins, preventing polymerization of Serum Amyloid A (SAA) monomers and thereby interfering with SAA-induced immune cell activation.  
• All doses of Amilo-5MER were well tolerated with no clinically significant adverse events, and none considered related to the investigational product. 
• The company plans to submit an IND for mild to moderate ulcerative colitis in 2022.
• Price Action: GLMD shares are down 10.9% at $1.68 during the premarket session on Monday’s last check.